Cellectar Biosciences
€0.29
54
+€0.01+3.6% Monday 13:25
Statistics
Day High
0.26
Day Low
0.26
52W High
-
52W Low
-
Volume
9,000
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12MayExpected
Expected EPS
-1.885
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-41.01MNet Income
Analyst Ratings
7.59Average Price Target
The highest estimate is 7.59.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NV4.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap501.13M
Allogene Therapeutics
ALLO
Mkt Cap794.59M
Gilead Sciences
GILD
Mkt Cap161.85B
Novartis
NVS
Mkt Cap280.79B
AMGEN
AMGN
Mkt Cap185.74B
About
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Show more...
CEO
Mr. James V. Caruso
Employees
11
Country
United States
ISIN
US15117F8077
WKN
000A3DQSD
Listings
0 Comments
Share your thoughts
FAQ
What is Cellectar Biosciences stock price today?▼
The current price of NV4.F is €0.29 EUR — it has increased by +3.6% in the past 24 hours. Watch Cellectar Biosciences stock price performance more closely on the chart.
What is Cellectar Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cellectar Biosciences stocks are traded under the ticker NV4.F.
Is Cellectar Biosciences stock price growing?▼
NV4.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cellectar Biosciences has showed a +19.01% increase.
What is Cellectar Biosciences revenue for the last year?▼
Cellectar Biosciences revenue for the last year amounts to 0 EUR.
What is Cellectar Biosciences net income for the last year?▼
NV4.F net income for the last year is -41.01M EUR.
How many employees does Cellectar Biosciences have?▼
As of April 29, 2026, the company has 11 employees.
In which sector is Cellectar Biosciences located?▼
Cellectar Biosciences operates in the Health & Wellness sector.
When did Cellectar Biosciences complete a stock split?▼
The last stock split for Cellectar Biosciences was on June 24, 2025 with a ratio of 1:30.
Where is Cellectar Biosciences headquartered?▼
Cellectar Biosciences is headquartered in Florham Park, United States.